EVLO
Income statement / Annual
Last year (2022), Evelo Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Evelo Biosciences, Inc.'s net income was -$114.53 M.
See Evelo Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$78.55 M
|
$83.64 M
|
$69.62 M
|
$63.13 M
|
$39.89 M
|
$19.96 M
|
$9.13 M
|
| General & Administrative
Expenses |
$29.91 M
|
$31.75 M
|
$22.27 M
|
$23.23 M
|
$18.22 M
|
$7.57 M
|
$3.89 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$29.91 M
|
$31.75 M
|
$22.27 M
|
$23.23 M
|
$18.22 M
|
$7.57 M
|
$3.89 M
|
| Other Expenses |
$0.00 |
$486,000.00 |
-$1.37 M |
$1.08 M |
$1.16 M |
-$301,000.00 |
-$20,000.00 |
| Operating Expenses |
$108.47 M |
$115.40 M |
$91.89 M |
$86.36 M |
$58.10 M |
$27.53 M |
$13.03 M |
| Cost And Expenses |
$108.47 M |
$115.40 M |
$91.89 M |
$86.36 M |
$58.10 M |
$27.53 M |
$13.03 M |
| Interest Income |
$4,672.00 |
$3,612.00 |
$0.00 |
$1,049.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.67 M |
$3.61 M |
$2.11 M |
$1.05 M |
$1.56 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.06 M
|
$2.22 M
|
$2.03 M
|
$1,764.00
|
$1,935.00
|
$834.00
|
$495.00
|
| EBITDA |
-$106.35 M
|
-$115.40 M
|
-$91.89 M
|
-$86.36 M
|
-$58.10 M
|
-$26.70 M
|
-$12.53 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$5.13 M
|
-$6.35 M
|
-$1.37 M
|
$885,000.00
|
$1.16 M
|
-$516,000.00
|
-$307,000.00
|
| Income Before Tax |
-$113.60 M |
-$121.75 M |
-$93.26 M |
-$85.47 M |
-$56.95 M |
-$28.05 M |
-$13.33 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$930,000.00 |
$428,000.00 |
$409,000.00 |
$190,000.00 |
-$3.09 M |
$215,000.00 |
$287,000.00 |
| Net Income |
-$114.53 M |
-$122.18 M |
-$93.67 M |
-$85.66 M |
-$53.85 M |
-$28.05 M |
-$13.33 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-26.28 |
-46.18 |
-47.45 |
-53.49 |
-49.25 |
-149.98 |
-94.55 |
| EPS Diluted |
-26.28 |
-46.18 |
-47.45 |
-53.49 |
-49.25 |
-149.55 |
-94.06 |
| Weighted Average Shares
Out |
$4.36 M
|
$2.65 M
|
$1.97 M
|
$1.60 M
|
$1.09 M
|
$187,000.00
|
$141,000.00
|
| Weighted Average Shares
Out Diluted |
$4.36 M
|
$2.65 M
|
$1.97 M
|
$1.60 M
|
$1.09 M
|
$187,540.00
|
$141,737.00
|
| Link |
|
|
|
|
|
|
|
